After a very profitable decade on Microsoft’s board, Reid Hoffman is stepping down to focus on his AI drug discovery startup Manus.
Reid Hoffman says tracking AI token use can gauge adoption, but cautions it should be paired with context and not treated as a direct productivity metric.
Some Valley CEOs have condemned recent border patrol events, but Hoffman urges them to wield their influence more powerfully.